Anal Fissure Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

An anal fissure is a longitudinal tear or ulceration in the anoderm — the squamous epithelium lining the anal canal distal to the dentate line — caused by trauma from the passage of hard or large stools, prolonged diarrhoea, or vigorous anal intercourse. The condition is characterised by severe sharp or burning anal pain during and after defaecation, and is often associated with bright red rectal bleeding on the toilet paper or toilet bowl. Pain from anal fissure can be so severe that patients avoid defaecation, leading to stool retention, harder stools, and a self-perpetuating cycle of injury.

Anal fissures are classified as acute (less than 6 weeks duration, appearing as a fresh tear with clean edges) or chronic (more than 6 weeks, characterised by the classic triad of a visible midline ulcer exposing the underlying white internal anal sphincter (IAS) fibres, a sentinel skin tag at the distal end, and a hypertrophied anal papilla at the proximal end). Approximately 90% of fissures occur in the posterior midline — the site of poorest mucosal blood supply — and 10% anteriorly (more common in women and obstetric-related cases). Lateral fissures should raise suspicion for secondary causes: Crohn's disease, sexually transmitted infections (syphilis, herpes, HIV), tuberculosis, or anal carcinoma.

The fundamental pathophysiology of chronic fissure involves elevated resting IAS tone (demonstrable on anorectal manometry), which reduces mucosal blood flow to the posterior commissure, impairing healing and perpetuating the spasm-ischaemia-non-healing cycle. Treatment rationale therefore focuses on IAS relaxation — via pharmacological (nitrates, calcium channel blockers, botulinum toxin) or surgical (lateral internal sphincterotomy) means — to restore mucosal blood flow and allow fissure healing.

• Acute anal fissure: Duration less than 6 weeks. Fresh tear in the posterior or anterior midline. Conservative management (high-fibre diet, adequate hydration, stool softeners, warm sitz baths, topical local anaesthetic — lidocaine 5% ointment) achieves healing in 40–60% of cases without specific pharmacological intervention.
• Chronic anal fissure: Duration more than 6 weeks; evidence of chronicity (sentinel tag, hypertrophied papilla, exposed IAS fibres at the base). Requires active pharmacological or surgical intervention; healing with conservative measures alone unlikely.
• Primary (idiopathic) fissure: The majority — no identifiable secondary cause. Associated with constipation, low-fibre diet, sedentary lifestyle, and elevated resting anal sphincter pressure.
• Secondary anal fissure: Associated with Crohn's disease (fissures may be deep, wide, off-midline, and multiple), ulcerative colitis, sexually transmitted infections, anal carcinoma, tuberculosis, or prior anal surgery. Investigation and treatment of the underlying condition is essential — topical nitrates and standard sphincterotomy are generally contraindicated in Crohn's-related fissures due to risk of poor healing and fistula formation.
• Postpartum fissure: Anterior midline fissures occurring after vaginal delivery, associated with obstetric sphincter injury. Management must avoid any further sphincter compromise; botulinum toxin is the preferred treatment.

Medical/pharmacological treatment is first-line for all acute and most chronic fissures:

• Topical glyceryl trinitrate (GTN) 0.2–0.4% ointment applied twice daily — appropriate for all patients with acute or chronic fissure, primary or postpartum; main side effect is headache (10–30%), requiring dose reduction or switch to calcium channel blocker if intolerable
• Topical diltiazem 2% or nifedipine 0.2–0.5% cream — equivalent efficacy to GTN with fewer headache side effects; suitable alternative for GTN-intolerant patients
• Botulinum toxin injection — appropriate for patients with chronic fissure failing 8–12 weeks of topical therapy, or with contraindications to topical nitrates (severe hypotension, concurrent PDE5 inhibitor use). Given as an outpatient procedure (20–80 units Botox injected into the IAS under local anaesthesia, or under light sedation)

Surgical lateral internal sphincterotomy (LIS) candidates:

• Chronic fissure that has failed adequate medical therapy (8–12 weeks GTN or CCB, plus at least one session of botulinum toxin)
• Pre-operative anorectal physiology (manometry) is recommended to assess resting IAS pressure and sphincter integrity before sphincterotomy
• Caution: patients with borderline sphincter function, previous obstetric injury, prior anorectal surgery, Crohn's disease, or pre-existing incontinence — sphincterotomy carries unacceptable incontinence risk in these groups; advancement flap or repeat botulinum toxin preferred

Conservative measures (all patients): High-fibre diet (25–30 g/day), adequate fluid intake (1.5–2 litres/day), osmotic or bulk-forming laxatives (lactulose, psyllium), warm sitz baths for 15–20 minutes twice daily, and topical local anaesthetic (lidocaine 5% gel) before defaecation for pain relief. These measures alone heal 40–60% of acute fissures within 4–6 weeks.

Topical nitrates: GTN 0.2–0.4% ointment (Rectogesic, Rectiv) applied to the anal margin twice daily relaxes the IAS via nitric oxide-mediated smooth muscle relaxation. Cochrane meta-analysis confirms healing rates of 48–52% versus 35% placebo at 6–8 weeks. Headache is the dose-limiting side effect. Titrate from once daily to twice daily as tolerated. Continue for 8 weeks minimum.

Topical calcium channel blockers: Diltiazem 2% cream or nifedipine 0.3% gel twice daily achieve healing rates of 65–70% at 8 weeks with fewer headache side effects than GTN. Available compounded at specialist pharmacies or commercially (Anoheal diltiazem). Equivalent efficacy to GTN; preferred in GTN headache non-tolerators.

Botulinum toxin (Botox) injection: 20–50 units (Botox) or 50–125 units (Dysport) injected into the IAS (bilateral posterior or intersphincteric approach) causes temporary chemical denervation (3–4 months duration) allowing fissure healing. Healing rate: 60–80% at 3 months. Risk of temporary incontinence for flatus or liquid stool in 5–10% — resolves spontaneously as toxin wears off. Repeat injection effective in many initial failures.

Lateral internal sphincterotomy (LIS — closed or open technique): Surgical division of the lower third of the IAS via a lateral intersphincteric groove approach. Closed LIS uses a narrow scalpel inserted blindly; open LIS visualises and divides the IAS directly under vision. Healing rate 92–97%, recurrence 2–5%. The gold standard for medically refractory chronic fissure. Performed under general or local anaesthesia as a day-case procedure. Disposable device-based sphincterotomy (e.g., Diltiazem-releasing sphincterotome) is under evaluation.

Advancement flap repair: A rotational or island flap of perianal skin or anodermal tissue is mobilised to cover the fissure base, bringing a well-vascularised tissue bridge. Used when sphincterotomy is contraindicated due to sphincter weakness. Healing rate 70–90% but technically more complex and reserved for specialist colorectal units.

• High healing rates with minimal treatment: Conservative management heals 40–60% of acute fissures without prescription medication. Topical pharmacotherapy heals 50–70% of chronic fissures, avoiding the need for any procedure or surgery in the majority of patients.
• Botulinum toxin — minimally invasive with low risk: Outpatient injection achieves 60–80% healing with a near-zero risk of permanent incontinence — the main concern with surgical sphincterotomy. Temporary (3–4 month) partial incontinence for flatus occurs in 5–10% and resolves fully as the toxin effect wears off.
• Definitive surgical cure: Lateral internal sphincterotomy achieves permanent healing in 92–97% of chronic fissures with 2–5% recurrence — the most effective treatment available. For patients who have failed all medical and injection therapy, LIS provides a reliable, definitive solution.
• Rapid pain relief: Patients who respond to topical nitrates typically report significant reduction in post-defaecation pain within 1–2 weeks of starting treatment, substantially improving quality of life. After LIS, the high resting IAS tone driving pain is immediately eliminated, with most patients reporting dramatic pain improvement within 24–48 hours.
• Ambulatory treatment: All non-surgical treatments and botulinum toxin injection are outpatient procedures. LIS itself is a day-case operation with discharge on the same day in most cases.

• Topical nitrates — headache: Headache from systemic nitrate absorption occurs in 10–30% of patients and is the most common cause of treatment discontinuation. Applying GTN with a fingertip rather than inserting into the anal canal, dosing once daily initially, and taking GTN headache-prophylactic paracetamol reduces but does not eliminate this effect. Switching to diltiazem cream circumvents headache in most patients.
• Botulinum toxin — incontinence: Temporary incontinence for flatus or liquid stool in 5–10%, resolving spontaneously at 3–4 months as the toxin degrades. Perianal haematoma at injection site in 2–3%. Theoretical risk of systemic botulism (weakness, diplopia) at doses used for fissure treatment is negligible.
• Lateral internal sphincterotomy — incontinence: Minor soiling or urgency in 5–15%; significant incontinence (requiring pads) in under 5% in experienced hands. Risk is higher in women with prior obstetric injury, patients with pre-existing marginal sphincter function, and when excessive IAS is divided. Pre-operative manometry guides safe surgical planning. Wound infection: 1–2%. Recurrence or non-healing fissure: 2–8%.
• Failure of conservative treatment: Approximately 30–50% of chronic fissures treated with topical agents alone fail to heal completely and require botulinum toxin or surgical intervention. Close follow-up at 6–8 weeks identifies non-responders for treatment escalation.

For topical medical treatment, patients are reviewed at 6–8 weeks to assess healing. Pain assessment (using a visual analogue scale) and clinical examination confirm whether the fissure is healing, unchanged, or worsened. Topical treatment is continued for a full 8 weeks before declaring failure; partial response warrants continuation for a further 4–8 weeks. Healed fissures may occasionally recur — reinstituting topical treatment and addressing the precipitating cause (constipation) is usually effective.

After botulinum toxin injection, follow-up at 6 weeks assesses healing progress. Most responders show significant improvement within 4–6 weeks; healing may continue up to 12 weeks as the fissure base gradually fills in. Patients who heal after one injection but then develop recurrence (20–30% within 12 months) may receive a second injection. The procedure can be safely repeated.

After lateral internal sphincterotomy, most patients are discharged on the day of surgery with oral analgesia (paracetamol, NSAIDs). Warm sitz baths twice daily and continued high-fibre diet and laxatives are recommended for 4–6 weeks. A wound review at 2–4 weeks assesses healing and identifies wound infection. Most patients report complete pain relief within the first week post-operatively — the immediate elimination of sphincter spasm is the most gratifying aspect of surgical treatment from the patient perspective.

Anal fissure treatment costs are modest for pharmacological approaches and moderate for surgical intervention. In India, topical compounded diltiazem or GTN cream costs USD 5–20 per tube (4–8 week supply); stool softeners and fibre supplements add USD 10–30 per month. Outpatient colorectal consultation at a specialist centre costs USD 30–80. Botulinum toxin injection (20–50 units Botox under local anaesthesia) at an accredited hospital costs USD 150–450 all-inclusive. Lateral internal sphincterotomy (day-case procedure under spinal or general anaesthesia) at JCI/NABH-accredited hospitals costs USD 400–1,500 including theatre, anaesthesia, and overnight stay if required.

In the USA, outpatient colorectal specialist consultation costs USD 250–500; botulinum toxin injection as an office or outpatient procedure USD 800–2,500 (device charge for toxin alone USD 400–600). LIS under general anaesthesia in a hospital setting costs USD 5,000–15,000. Many insurance plans cover botulinum toxin and LIS for chronic fissure as medically necessary procedures. Thailand: LIS USD 1,500–4,000 at international hospitals; Turkey USD 1,000–3,000. For UK NHS patients, outpatient treatment with topical agents is prescribable (cost: one NHS prescription charge); botulinum toxin injection and LIS are performed on the NHS waitlist, though private sector options are available at GBP 500–3,000.

Minaxolone cream — a neurosteroid modulating GABA receptors and reducing anal sphincter tone — is under clinical trial evaluation for fissure. Sildenafil cream (a PDE5 inhibitor increasing nitric oxide availability) has shown preliminary efficacy in small studies as an alternative to GTN without the headache side effect profile.

Pneumatic balloon dilation of the anal canal (1.5–2 cm balloon inflated to 1.5 kg/cm² pressure for 6 minutes under anaesthesia) achieves 80–85% healing in some series without the targeted specificity of LIS, but with higher rates of incontinence from uncontrolled sphincter trauma — not recommended by most colorectal societies as first-choice surgical option.

For Crohn's disease–related fissures, systemic treatment of the underlying IBD (biologics, steroids, immunomodulators) combined with metronidazole-based topical preparations is the primary approach; sphincterotomy is generally avoided. Setons (ligatures threaded through fistulas associated with Crohn's fissures) manage septic complications while preserving sphincter function.

General lifestyle measures including adequate dietary fibre (25–35 g/day), hydration, regular exercise, and avoiding prolonged sitting on the toilet are essential adjuncts to all specific treatments and help prevent recurrence after successful healing.